Brokerages Set West Pharmaceutical Services, Inc. (NYSE:WST) PT at $340.09

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) have earned a consensus rating of “Buy” from the fourteen research firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $340.0909.

WST has been the subject of a number of recent analyst reports. Morgan Stanley increased their price target on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the company an “equal weight” rating in a research note on Friday, May 29th. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, April 27th.

Insider Activity

In other news, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the transaction, the vice president directly owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Chad Winters sold 896 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer directly owned 1,523 shares in the company, valued at $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On West Pharmaceutical Services

Large investors have recently modified their holdings of the stock. Elyxium Wealth LLC bought a new position in shares of West Pharmaceutical Services in the fourth quarter valued at about $25,000. Bayban bought a new position in shares of West Pharmaceutical Services in the fourth quarter valued at about $27,000. Private Trust Co. NA raised its position in shares of West Pharmaceutical Services by 156.4% in the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 61 shares during the period. DV Equities LLC bought a new position in West Pharmaceutical Services during the fourth quarter worth about $28,000. Finally, Cornerstone Planning Group LLC increased its position in West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 50 shares during the period. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $328.48 on Tuesday. West Pharmaceutical Services has a 12 month low of $206.80 and a 12 month high of $336.82. The firm has a fifty day simple moving average of $305.93 and a 200 day simple moving average of $273.41. The stock has a market capitalization of $23.21 billion, a price-to-earnings ratio of 43.91, a PEG ratio of 2.74 and a beta of 1.18. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm’s revenue was up 21.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Research analysts forecast that West Pharmaceutical Services will post 8.6 EPS for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.